Characterization of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer and glioblastoma multiforme.

BTX-9341 - BioTheryX

Ibrance (palbociclib) - Pfizer

fulvestrant - Generic mfg.

https://meetings.asco.org/abstracts-presentations/234124/

Hannah Majeski; Kirti Chahal; Angela Pasis; Casey Carlson; Qiao Liu; Arvind Shakya; Akinori Okano; Shenlin Huang; Aparajita Hoskote Chourasia; Leah M. Fung

Apr 25, 2024